Option Care Health (OPCH) vs GeneDx (WGS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Option Care Health (OPCH) has outperformed GeneDx (WGS) over the past year, gaining 14.2% versus a loss of 44.8%. Over five years, OPCH leads with a +26.9% price change compared with -73.7% for WGS. Option Care Health is the larger company by market cap ($4.66 billion vs $2.03 billion), about 2.3 times the size, while GeneDx is growing revenue faster (+40.0% vs +13.0%).
On valuation, Option Care Health trades at a lower forward P/E (14.9x vs 56.8x for GeneDx). Option Care Health converts more of its revenue into profit, with a net margin of 3.7% versus -4.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OPCH | WGS |
|---|---|---|
| Share price | $31.08 | $68.07 |
| Market cap | $4.66B | $2.03B |
| 1-day change | +0.10% | +0.49% |
| YTD return | -2.54% | -47.92% |
| 1-year return | +14.20% | -44.80% |
| 5-year return | +26.94% | -73.65% |
| P/E ratio (TTM) | 23.55 | — |
| Forward P/E | 14.92 | 56.79 |
| EPS (TTM) | $1.32 | $-3.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.65B | $427.54M |
| Revenue growth (YoY) | +13.03% | +39.97% |
| Net income (latest FY) | $207.59M | $-21.02M |
| Gross margin | 19.26% | 69.74% |
| Operating margin | 5.98% | -3.06% |
| Net margin | 3.67% | -4.92% |
| 52-week high | $36.80 | $170.87 |
| 52-week low | $18.01 | $32.21 |
| Distance from 52-week high | -15.54% | -60.17% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -1.29% | +37.37% |
| Average volume | 3.57M | 730.21K |
| Shares outstanding | 149.79M | 29.82M |
| Employees | 8,000 | 1,300 |
| Sector | Health Care | Health Care |
| Industry | Medical/Nursing Services | Medical/Nursing Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Option Care Health is about 2.3 times larger than GeneDx by market value ($4.66B vs $2.03B).
- OPCH has outperformed WGS by 59.0 percentage points over the past year.
- Option Care Health is more profitable, keeping 3.7 cents of every revenue dollar as net income versus -4.9 cents for GeneDx.
- GeneDx grew revenue faster in its latest fiscal year (+39.97% vs +13.03%).
About Option Care Health
OPCH stock →Option Care Health, Inc. offers home and alternate site infusion services in the United States.
Health Care · Medical/Nursing Services · 8,000 employees
About GeneDx
WGS stock →GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Health Care · Medical/Nursing Services · 1,300 employees
OPCH vs WGS FAQ
Which is bigger, Option Care Health or GeneDx?
Option Care Health (OPCH) is larger, with a market capitalization of $4.66B compared with $2.03B for GeneDx (WGS).
Which stock has performed better over the past year, OPCH or WGS?
OPCH returned +14.20% over the past 12 months, compared with -44.80% for WGS (price return, excluding dividends). Past performance does not predict future results.
Are Option Care Health and GeneDx in the same industry?
Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.